Shield Therapeutics PLC Registered Shares LS -,015
- BID
0.068
- ASK
0.078
- 49,412 Units25,641 Units
- 07/21, 21:56:51 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
119.35%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.01 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 0.068 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:56:51 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 0.0685 | 0.068 |
| PREV. DAY'S PRICE | 0.068 | (07/20) |
| CHANGE DAY BEFORE | +0.00 | 0.00 % |
| 52 WEEK HIGH / LOW | 0.152 (12/29) | 0.031 (07/21) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.04 | -0.03 | -0.01 | 0.00 | 0.00 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | 300.92 |
PRICE - BOOK RATIO | 4.44 | - | - | - | - |
PRICE - SALES RATIO | 4.60 | 0.84 | 2.74 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A2AE98 |
| ISIN | GB00BYV81293 |
| SYMBOL | 1JS |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | SHIELD THERAPEUT. LS-,015 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 0.00 % | 0.00 % | -27.27 % | -38.18 % | 119.35 % | -15.53 % | -85.09 % | -38.18 % |
| HIGH | 0.08 | 0.08 | 0.10 | 0.14 | 0.15 | 0.15 | 0.58 | 0.15 |
| LOW | 0.06 | 0.06 | 0.05 | 0.03 | 0.03 | 0.01 | 0.01 | 0.03 |
Dividende
pro Aktie
SHIELD THERAPEUT. LS-,015 does not deliver dividend information
Company profile
Shield Therapeutics Plc is a commercial stage specialty pharmaceutical company, which engages in addressing iron deficiency with its lead product Accrufer. It operates the Feraccru and PT20 segments. The Feraccru segment refers to the development and commercialization of this product. The PT20 segment related to the development of its secondary asset. The company was founded by Carl Sterritt and Christian Schweiger in 2008 and is headquartered in Gateshead Quays, the United Kingdom.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.